Redx Pharma PLC
LSE:REDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Redx Pharma PLC
Total Liabilities & Equity
Redx Pharma PLC
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Redx Pharma PLC
LSE:REDX
|
Total Liabilities & Equity
£25.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Total Liabilities & Equity
£61.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Total Liabilities & Equity
$114.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Total Liabilities & Equity
$5.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Total Liabilities & Equity
£67.5m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Total Liabilities & Equity
£369.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
13%
|
|
Redx Pharma PLC
Glance View
Redx Pharma Plc engages in the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. The company is headquartered in Macclesfield, Cheshire and currently employs 71 full-time employees. The company went IPO on 2015-03-27. The Company’s product pipeline includes RXC004 and ROC007. Its lead product candidate RXC004, which is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. RXC004 is in Phase I study in combination with nivolumab (OPDIVO- Bristol Myers Squibb, an anti-PD-1 antibody). The RXC007 is a selective small molecule inhibitor that targets Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signaling pathway. RXC007 is used for the treatment of fibrotic diseases.
See Also
What is Redx Pharma PLC's Total Liabilities & Equity?
Total Liabilities & Equity
25.6m
GBP
Based on the financial report for Sep 30, 2023, Redx Pharma PLC's Total Liabilities & Equity amounts to 25.6m GBP.
What is Redx Pharma PLC's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
20%
Over the last year, the Total Liabilities & Equity growth was -59%. The average annual Total Liabilities & Equity growth rates for Redx Pharma PLC have been -8% over the past three years , 20% over the past five years .
